Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) | MicrobiomeTrials← Back to trialsNCT07717580
Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-31Est. Completion: 2028-12-30
Enrollment target: 46 participants Locations- Peking University First Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
T-Cell Non-Hodgkin LymphomaAcute Myeloid LeukemiaAngioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell LymphomaAdult T Cell LeukemiaAdult T Cell LymphomaT Cell Prolymphocytic LeukemiaExtranodal NK/T-cell LymphomaTransformed Mycosis FungoidesSezary SyndromePrimary Cutaneous Gamma-Delta T-Cell LymphomaHepatosplenic T-cell Lymphoma
Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL)…
St Louis, United StatesCompleted Jun 30, 2027
Folliculotropic Mycosis FungoidesRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRefractory Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedSezary SyndromeRecurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with …
Duarte, United StatesEst. completion Apr 14, 2030